S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

JANX Janux Therapeutics Inc

54.10

-1.07 (-1.94%)

Dec 27 2024 - Closed

Delayed by 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Janux Therapeutics Charts.

Janux Therapeutics (NASDAQ:JANX)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Janux Therapeutics Charts.

Janux Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Friday 27 December 2024 (15 hours ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 26 December 2024 (2 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 December 2024 (1 week ago) • Edgar (US Regulatory)

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Friday 6 December 2024 (3 weeks ago) • Business Wire

Form 8-K - Current report
Thursday 5 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 5 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Wednesday 4 December 2024 (3 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 3 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Tuesday 3 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Janux Therapeutics Announces Proposed Public Offering
Tuesday 3 December 2024 (4 weeks ago) • Business Wire

Form 8-K - Current report
Monday 2 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
Monday 2 December 2024 (4 weeks ago) • Business Wire

More Janux Therapeutics Inc News Articles

XS2675108570 20270929 13...

XS2803385751 20340531 19...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions